MECHANISMS OF PROTECTION FROM AND ENHANCED SUSCEPTIBILITY TO HIV INFECTION

预防艾滋病毒感染和增加艾滋病毒感染易感性的机制

• 批准号: 8357343
• 负责人: CHRISTOPHER James MILLER
• 金额: $ 19.14万
• 依托单位: UNIVERSITY OF CALIFORNIA AT DAVIS
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8357343
• 关键词: Adenoviruses; California; Effectiveness; Funding; Grant; HIV; HIV Infections; Immune; Inflammation; Macaca mulatta; Modeling; National Center for Research Resources; Predisposition; Primates; Principal Investigator; Research; Research Infrastructure; Resources; SIV; Source; United States National Institutes of Health; Vaccines; cost; research study; transmission process; vector vaccine

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The key to understanding the results of the STEP/Phambili trials is first to model the results of the trial in controlled experiments using mucosal SIV inoculation of rhesus macaques. Thus, we will determine the effectiveness and potential of the Merck trivalent HIV adenovirus 5 vector vaccine (V520) for enhancing susceptibility to S1V in a rhesus macaque model of mucosal HIV transmission. If models of vaccine protection or enhancement are established, the immune mechanisms and inflammation/activation associated with any protective or enhancing effects can be defined in a renewal application.

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 理解STEP/Phambili试验结果的关键是首先在使用恒河猴粘膜SIV接种的对照实验中模拟试验结果。因此，我们将确定默克三价HIV腺病毒5载体疫苗(V520)在恒河猴粘膜传播HIV模型中增强S1V易感性的有效性和潜力。如果建立了疫苗保护或增强的模型，与任何保护或增强效果相关的免疫机制和炎症/激活可以在更新申请中定义。